共 50 条
Dendritic cells in cancer immunology and immunotherapy
被引:1214
|作者:
Wculek, Stefanie K.
[1
]
Cueto, Francisco J.
[1
]
Mujal, Adriana M.
[2
,7
]
Melero, Ignacio
[3
,4
,5
,6
]
Krummel, Matthew F.
[2
]
Sancho, David
[1
]
机构:
[1] CNIC, Immunobiol Lab, Madrid, Spain
[2] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA
[3] Univ Navarra, Ctr Appl Med Res, Div Immunol & Immunotherapy, Pamplona, Spain
[4] Inst Invest Sanitaria Navarra, Pamplona, Spain
[5] Univ Navarra, Univ Clin, Pamplona, Spain
[6] Ctr Invest Biomed Red Canc, Madrid, Spain
[7] Mem Sloan Kettering Canc Ctr, Immunol Program, 1275 York Ave, New York, NY 10021 USA
基金:
欧洲研究理事会;
欧盟地平线“2020”;
关键词:
ANTIGEN CROSS-PRESENTATION;
CD8(+) T-CELLS;
IMMUNE-RESPONSES;
ANTITUMOR IMMUNITY;
BETA-CATENIN;
FLT3;
LIGAND;
ANTICANCER CHEMOTHERAPY;
COINHIBITORY RECEPTOR;
I INTERFERON;
VACCINES;
D O I:
10.1038/s41577-019-0210-z
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Dendritic cells (DCs) are a diverse group of specialized antigen-presenting cells with key roles in the initiation and regulation of innate and adaptive immune responses. As such, there is currently much interest in modulating DC function to improve cancer immunotherapy. Many strategies have been developed to target DCs in cancer, such as the administration of antigens with immunomodulators that mobilize and activate endogenous DCs, as well as the generation of DC-based vaccines. A better understanding of the diversity and functions of DC subsets and of how these are shaped by the tumour microenvironment could lead to improved therapies for cancer. Here we will outline how different DC subsets influence immunity and tolerance in cancer settings and discuss the implications for both established cancer treatments and novel immunotherapy strategies.
引用
收藏
页码:7 / 24
页数:18
相关论文